99 related articles for article (PubMed ID: 20054647)
21. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
[TBL] [Abstract][Full Text] [Related]
25. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
26. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.
Marconett CN; Morgenstern TJ; San Roman AK; Sundar SN; Singhal AK; Firestone GL
Cancer Biol Ther; 2010 Aug; 10(4):397-405. PubMed ID: 20574166
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2
Moulder SL; Borges VF; Baetz T; Mcspadden T; Fernetich G; Murthy RK; Chavira R; Guthrie K; Barrett E; Chia SK
Clin Cancer Res; 2017 Jul; 23(14):3529-3536. PubMed ID: 28053022
[No Abstract] [Full Text] [Related]
28. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.
Fong S; Shoemaker M; Cadaoas J; Lo A; Liao W; Tagliaferri M; Cohen I; Shtivelman E
Cancer Biol Ther; 2008 Apr; 7(4):577-86. PubMed ID: 18305410
[TBL] [Abstract][Full Text] [Related]
30. A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer.
Cheon C; Ko SG
Integr Cancer Ther; 2020; 19():1534735420911442. PubMed ID: 32186413
[No Abstract] [Full Text] [Related]
31. Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol.
Cheon C; Ko SG
Medicine (Baltimore); 2020 Sep; 99(38):e22228. PubMed ID: 32957363
[TBL] [Abstract][Full Text] [Related]
32. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
33. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Crew KD; Brown P; Greenlee H; Bevers TB; Arun B; Hudis C; McArthur HL; Chang J; Rimawi M; Vornik L; Cornelison TL; Wang A; Hibshoosh H; Ahmed A; Terry MB; Santella RM; Lippman SM; Hershman DL
Cancer Prev Res (Phila); 2012 Sep; 5(9):1144-54. PubMed ID: 22827973
[TBL] [Abstract][Full Text] [Related]
34. Current therapeutic role and medicinal potential of Scutellaria barbata in Traditional Chinese Medicine and Western research.
Tao G; Balunas MJ
J Ethnopharmacol; 2016 Apr; 182():170-80. PubMed ID: 26875645
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer.
Schmidt M; Lenhard H; Hoenig A; Zimmerman Y; Krijgh J; Jansen M; Coelingh Bennink HJT
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1833-1842. PubMed ID: 33242131
[TBL] [Abstract][Full Text] [Related]
36. A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer.
Sukumaran S; Pittman KB; Patterson WK; Dickson J; Yeend S; Townsend A; Broadbridge V; Price TJ
Ann Oncol; 2010 May; 21(5):1089-93. PubMed ID: 19846468
[TBL] [Abstract][Full Text] [Related]
37. Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol.
Cheon C; Kang S; Ko Y; Kim M; Jang BH; Shin YC; Ko SG
BMJ Open; 2018 Aug; 8(8):e019502. PubMed ID: 30082340
[TBL] [Abstract][Full Text] [Related]
38. An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations.
Ivanova A; Murphy M
J Biopharm Stat; 2009; 19(2):247-55. PubMed ID: 19212877
[TBL] [Abstract][Full Text] [Related]
39. [Use of herbal medicine for cancer treatment-related toxicities].
Samuels N; Morag O; Maimon Y
Harefuah; 2015 Jan; 154(1):43-6, 67. PubMed ID: 25796675
[TBL] [Abstract][Full Text] [Related]
40. Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).
Jung S; Schlenk RF; Hackenbruch C; Roldan Pinzon SSL; Bitzer M; Pflügler M; Walz JS; Jung G; Heitmann JS; Salih HR
Front Oncol; 2024; 14():1351901. PubMed ID: 38410109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
